HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

CEP 8983

inhibits PAR polymerase-1 and PAR polymerase-2; structure in first source

Also Known As:

CEP-8983; CEP8983

Networked: 4 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Busschots, Steven: 2 articles (08/2015 - 06/2014)
2.	O'Leary, John J: 2 articles (08/2015 - 06/2014)
3.	Stordal, Britta: 2 articles (08/2015 - 06/2014)
4.	O'Toole, Sharon: 1 article (08/2015)
5.	Hennessy, Bryan T: 1 article (06/2014)
6.	Lawlor, Denise: 1 article (06/2014)
7.	Martin, Patricia: 1 article (06/2014)
8.	Thery, Julien: 1 article (06/2014)
9.	Dilley, Robert L: 1 article (03/2014)
10.	Gladstone, Douglas E: 1 article (03/2014)

Related Diseases

1.	Ovarian Neoplasms (Ovarian Cancer) 06/01/2014 - "Veliparib and CEP-8983 may therefore be more useful in combined chemotherapy regimens with P-gp substrates and may be active in platinum and taxane-resistant ovarian cancer." 08/01/2015 - "The UPN251 sublines remain sensitive to parp inhibitors veliparib and CEP8983 suggesting that these agents are candidates for the treatment of platinum/taxane resistant ovarian cancer patients."
2.	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 03/01/2014 - "Poly(ADP-ribose) polymerase inhibitor CEP-8983 synergizes with bendamustine in chronic lymphocytic leukemia cells in vitro."
3.	Rhabdomyosarcoma 08/01/2007 - "The effect of the potent and selective poly(ADP-ribose) (PAR) polymerase-1 [and PAR polymerase-2] inhibitor CEP-8983 on the ability to sensitize chemoresistant glioblastoma (RG2), rhabdomyosarcoma (RH18), neuroblastoma (NB1691), and colon carcinoma (HT29) tumor cells to temozolomide- and camptothecin-induced cytotoxicity, DNA damage, and G(2)-M arrest and on the potentiation of chemotherapy-induced myelotoxicity was evaluated using in vitro assays. "
4.	Neuroblastoma 08/01/2007 - "The effect of the potent and selective poly(ADP-ribose) (PAR) polymerase-1 [and PAR polymerase-2] inhibitor CEP-8983 on the ability to sensitize chemoresistant glioblastoma (RG2), rhabdomyosarcoma (RH18), neuroblastoma (NB1691), and colon carcinoma (HT29) tumor cells to temozolomide- and camptothecin-induced cytotoxicity, DNA damage, and G(2)-M arrest and on the potentiation of chemotherapy-induced myelotoxicity was evaluated using in vitro assays. "
5.	Neoplasms (Cancer) 08/01/2007 - "These data indicate that CEP-8983 and its prodrug are effective chemosensitizing agents when administered in combination with select chemotherapeutic agents against chemoresistant tumors." 08/01/2007 - "CEP-8983 sensitized carcinoma cells to the growth-inhibitory effects of temozolomide and/or SN38 increased the fraction of and/or lengthened duration of time tumor cells accumulated in chemotherapy-induced G(2)-M arrest and sensitized tumor cells to chemotherapy-induced DNA damage and apoptosis. " 08/01/2007 - "The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity." 08/01/2007 - "The effect of the potent and selective poly(ADP-ribose) (PAR) polymerase-1 [and PAR polymerase-2] inhibitor CEP-8983 on the ability to sensitize chemoresistant glioblastoma (RG2), rhabdomyosarcoma (RH18), neuroblastoma (NB1691), and colon carcinoma (HT29) tumor cells to temozolomide- and camptothecin-induced cytotoxicity, DNA damage, and G(2)-M arrest and on the potentiation of chemotherapy-induced myelotoxicity was evaluated using in vitro assays. "

Related Drugs and Biologics

1.	Platinum
2.	Poly(ADP-ribose) Polymerase Inhibitors
3.	veliparib
4.	taxane
5.	Prodrugs
6.	Poly Adenosine Diphosphate Ribose
7.	Camptothecin
8.	Temozolomide (Temodar)
9.	Irinotecan (Camptosar)
10.	Bendamustine Hydrochloride

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)